– USA, NY – Chembio Diagnostics, Inc. (NASDAQ: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the appointment of Dr. David Acheson, M.D. to its Board of Directors.
“We are pleased to welcome David to our Board of Directors. He adds directly applicable expertise in public health and infectious disease management to our leadership team, and we are confident his perspective will contribute meaningfully to our long-term value creation strategy,” said Board chair, Katherine Davis. “We look forward to his leadership and insights as we enter the next phase of growth for Chembio.”
About Dr. David Acheson
Dr. David Acheson has served as the President and CEO of The Acheson Group since founding the global food safety consulting group in 2013. Previously he served as a Partner and Managing Director of Leavitt Partners, where he founded and managed the firm’s food safety services business. Before his industry roles, Dr. Acheson served at the U.S. Food and Drug Administration for eight years in various positions, progressing from Chief Medical Officer of the Center for Food Safety and Applied Nutrition to Associate Commissioner for Foods.
Dr. Acheson began his career practicing medicine in the United Kingdom and later at the New England Medical Center, where he also served as an Associate Professor for Tufts University while researching foodborne pathogens.
“The unique features and versatility of Chembio’s proprietary DPP technology platform make it uniquely suited for use across the entire healthcare landscape. This is a transformational time for the diagnostics industry as the global COVID-19 pandemic sheds light on the true value of point-of-care testing,” said Dr. Acheson. “I believe the DPP platform can not only make an impact as a COVID-19 testing solution but also be leveraged to offer innovative diagnostic tests for the future. I am excited about the opportunity ahead for Chembio and to work with this team to drive the adoption of the technology in the US and around the world.”
Dr. Acheson received his Medical Doctor degree from the University of London Medical School. He is a Fellow of the Royal College of Physicians (London) and the Infectious Disease Society of America.
About Chembio Diagnostics
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.
For more information: https://chembio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
